Quotient Sciences Advances AI Designed Drug Product into Clinical Development
Phase I study of an AI-designed oral formulation sets a new standard in drug development
NOTTINGHAM, UK – 28 MAY 2026: Quotient Sciences today announces the successful initiation of a clinical study evaluating a novel drug product developed using artificial intelligence (AI) - a landmark achievement highlighting the growing potential of AI to guide formulation design and accelerate drug development.